Fig. 5: Network activity of drug targets across subtypes.
From: Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma
a Targets of established baseline therapies. IMiDs: CRBN, IKZF1, IKZF3; dexamethasone: NR3C1; bortezomib and carfilzomib: PSMB5. b Targets of therapies in clinical trials for relapse-refractory MM (RRMM). c Genes associated with proliferation. d Genes directly involved in the intrinsic apoptosis pathway demonstrate subtype-specific differences in network activity. e Risk-associated and proposed target genes. These genes either classify a subtype via their uniformly high expression or are selectively active in the low- or high-risk subset of a clinical subtype.
